Abstract
Purpose:
We present a case of a patient who developed seizures shortly after initiating treatment with levofloxacin and to discuss the potential drug-drug interactions related to the inhibition of cytochrome P450 (CYP) 1A2 in this case, as well as in other cases, of levofloxacin-induced seizures.
Methods:
Several biomedical databases were searched including MEDLINE, Cochrane and Ovid. The main search terms utilized were case report and levofloxacin. The search was limited to studies published in English.
Results:
Six cases of levofloxacin-induced seizures have been reported in the literature. Drug-drug interactions related to the inhibition of CYP1A2 by levofloxacin are likely involved in the clinical outcome of these cases.
Conclusions:
Clinicians are exhorted to pay close attention when initiating levofloxacin therapy in patients taking medications with epileptogenic properties that are CYP1A2 substrates.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Adrenergic alpha-Antagonists / adverse effects
-
Aged
-
Aged, 80 and over
-
Anti-Bacterial Agents / administration & dosage
-
Anti-Bacterial Agents / adverse effects*
-
Bacteremia / diagnosis
-
Bacteremia / microbiology*
-
Cytochrome P-450 CYP1A2 / drug effects
-
Cytochrome P-450 CYP1A2 / metabolism
-
Dopamine Antagonists / adverse effects
-
Drug Administration Schedule
-
Drug Synergism
-
Female
-
Humans
-
Klebsiella Infections / diagnosis*
-
Klebsiella Infections / drug therapy
-
Levofloxacin*
-
Male
-
Metoclopramide / adverse effects
-
Mianserin / adverse effects
-
Mianserin / analogs & derivatives
-
Middle Aged
-
Mirtazapine
-
Ofloxacin / administration & dosage
-
Ofloxacin / adverse effects*
-
Phosphodiesterase Inhibitors / adverse effects
-
Seizures / chemically induced*
-
Theophylline / adverse effects
Substances
-
Adrenergic alpha-Antagonists
-
Anti-Bacterial Agents
-
Dopamine Antagonists
-
Phosphodiesterase Inhibitors
-
Mianserin
-
Levofloxacin
-
Mirtazapine
-
Ofloxacin
-
Theophylline
-
Cytochrome P-450 CYP1A2
-
Metoclopramide